期刊
BLOOD REVIEWS
卷 32, 期 5, 页码 368-377出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2018.03.002
关键词
Myelodysplastic syndromes; Transfusion; Iron chelation; Deferasirox; Deferoxamine; Deferiprone
类别
资金
- Novartis Pharmaceuticals Corporation
Myelodysplastic syndromes (MDS) are a heterogeneous group of hemopathies that exhibit physical manifestations with clinical consequences of bone marrow failure and inherent risk of progression to acute myeloid leukemia. Iron overload (10) is common in MDS due to chronic transfusion support and disease-related alterations in iron metabolism. 10 has been conclusively associated with inferior outcomes among MDS patients. Despite lack of randomized trials showing a survival impact of iron chelation therapy (ICT), ICT is recommended by experts and guidelines for select MDS patients with IO and is often used. The availability of effective oral ICT agents has reignited the controversy regarding ICT use in patients with MDS and IO. Here we summarize the studies evaluating the value of ICT in MDS and suggest a practical approach for use of these therapies. We also highlight controversies regarding use of ICT in MDS and discuss some ongoing efforts to answer these questions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据